Xtant Medical (XTNT) Stock Price, News & Analysis

Company Overview

Xtant Medical, Inc. is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents. Xtant Medical leverages proprietary technologies to optimize handling characteristics and osteoinductive potential, with products that are used by surgeons in hospital operating rooms and outpatient surgical centers. The company also provides custom solutions through its product design and contract manufacturing services.

Headquartered in Carlsbad, California, Xtant Medical serves customers primarily across North America, with distribution partnerships extending to select international markets. Under the leadership of President and Chief Executive Officer Shawn Ainsworth, the company continues to expand its research and development capabilities and advance its regenerative medicine pipeline. Xtant Medical is dedicated to improving patient outcomes by delivering innovative, clinically driven solutions for spinal and orthopedic care.

Key Stats

• Today's Range: $0.62 to $0.64
• 50-Day Range: $0.55 to $0.67
• 52-Week Range: $0.33 to $0.78
• Volume: 85,320 shs
• Average Volume: 118,839 shs
• Market Capitalization: $88.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Buy

Xtant Medical Stock Analysis - MarketRank™

Xtant Medical scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Xtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Xtant Medical has a consensus price target of $1.50, representing about 136.2% upside from its current price of $0.64.

Amount of Analyst Coverage

Xtant Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Xtant Medical is -15.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xtant Medical is -15.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xtant Medical has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the outstanding shares of Xtant Medical have been sold short.

Short Interest Ratio / Days to Cover

Xtant Medical has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xtant Medical has recently increased by 44.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xtant Medical does not currently pay a dividend.

Dividend Growth

Xtant Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the outstanding shares of Xtant Medical have been sold short.

Short Interest Ratio / Days to Cover

Xtant Medical has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xtant Medical has recently increased by 44.99%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Xtant Medical has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Xtant Medical this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for XTNT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xtant Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Xtant Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XTNT Stock Analysis - Frequently Asked Questions

How have XTNT shares performed this year?

Xtant Medical's stock was trading at $0.4681 at the beginning of the year. Since then, XTNT stock has increased by 35.7% and is now trading at $0.6350.

How were Xtant Medical's earnings last quarter?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) issued its quarterly earnings results on Tuesday, November, 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. The medical device company earned $27.94 million during the quarter. Xtant Medical had a negative trailing twelve-month return on equity of 10.12% and a negative net margin of 3.59%.
Read the conference call transcript.

When did Xtant Medical's stock split?

Xtant Medical's stock reverse split on the morning of Wednesday, February 14th 2018.The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Xtant Medical?

Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xtant Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xtant Medical investors own include Meta Platforms (META), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 10/02/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:XTNT
• Previous Symbol: AMEX:XTNT
• CIK: 1453593
• Web: xtantmedical.com
• Phone: (406) 388-0480
• Fax: 406-388-1354
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xtant Medical: $1.50
• High Price Target: $1.50
• Low Price Target: $1.50
• Potential Upside/Downside: +132.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.45 million
• Net Margins: -3.59%
• Pretax Margin: -3.34%
• Return on Equity: -10.12%
• Return on Assets: -4.67%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 2.47
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $117.27 million
• Price / Sales: 0.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 2.09

Miscellaneous

• Outstanding Shares: 140,000,000
• Free Float: 125,440,000
• Market Cap: $90.50 million
• Optionable: Not Optionable
• Beta: -0.22